Tumor cells evade detection by exploiting inhibitory pathways and low receptor affinity. Enhancing effector cell engagement overcomes immune checkpoint-mediated suppression.

Inhibitory signaling through ILT3, ILT4, and checkpoint ligands prevents effective anti-tumor immune responses. Overcoming these suppressive pathways restores immune surveillance and therapeutic efficacy in hematologic and solid malignancies.

Monoclonal antibodies are prone to physical and chemical instability during storage. Preventing degradation ensures drug potency and patient safety in multi-antibody therapies.